Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study-Reference-Cited by-同舟云学术

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

Published:2019-01-09 Issue:6 Volume:60 Page:1563-1567
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chaoui Driss¹,Hacini Maya²,Fitoussi Olivier³,Karlin Lionel⁴,Arkam Yazid⁵,Jourdan Eric⁶,Orfeuvre Hubert⁷,Voillat Laurent⁸,Sanhes Laurence⁹,Leprêtre Stéphane¹⁰,Liu Kun Lun¹¹,Barry Marly¹²,Tempescul Adrian¹³,Dilhuydy Marie-Sarah¹⁴,Chaib Abdelaziz¹⁵,Slama Borhane¹⁶,Labourey Jean Luc¹⁷,Benbrahim Omar¹⁸,Dreyfus Brigitte¹⁹,Mahé Béatrice²⁰,Maynadié Marc²¹,Delmer Alain²²,Benkanoun Chahinez²³,Boissard Frédéric²³,Gandon Sophie²³,Veerabudun Kalaivani²⁴,Choquet Sylvain²⁵,

Affiliation:

1. Department of Hematology, Victor Dupouy Hospital, Argenteuil, France;

2. Department of Hematology, Chambéry Hospital, Chambéry, France;

3. Department of Hematology, Bordeaux Nord Clinic, Bordeaux, France;

4. CHU Lyon Sud, Lyon, France;

5. Department of Hematology, Émile Muller Hospital, Mulhouse, France;

6. Department of Hematology, Nîmes University Hospital, Nîmes, France;

7. Hospital Hematology, Centre Hospitalier de Fleyriat, Bourg en Bresse, France;

8. CH William Morey, Châlon sur Saone, France;

9. Department of Hematology, Saint-Jean Hospital, Perpignan, France;

10. Department of Hematology, Henri Becquerel Hospital, Rouen, France;

11. Hautepierre Hospital, Strasbourg, France;

12. Department of Hematology, Dr Duchenne Hospital, Boulogne sur Mer, France;

13. Department of Hematology, Auguste Morvan Hospital, Brest, France;

14. Department of Hematology, Bordeaux Pessac Hospital, Haut Levêque Hospital, Pessac, France;

15. CH Pays d’Aix, Aix en Provence, France;

16. CH Henri Duffaut, Avignon, France;

17. CH Carcassonne Antoine Gayraud, Carcassonne, France;

18. Hopital La Source, La Source, France;

19. Department of Hematology, Regional Oncology Center, Poitiers, France;

20. Department of Hematology, Nantes University Hospital, Nantes, France;

21. Department of Hematology, Bocage University Hospital, Dijon, France;

22. Department of Hematology, Robert Debré University Hospital, Reims, France;

23. Medical Affairs, Roche France, Boulogne-Billancourt, France;

24. Axial R&D, Boulogne-Billancourt, France;

25. Department of Hematology, La Pitié Salpêtrière Hospital, Paris, France

Funder

Roche

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1533130

Reference12 articles.

1. ESMO Guidelines Committee eUpdate [Internet]. Lugano (Switzerland); 2017 [published 2017 Jun 27; cited 2018 Sep]. Availale from: http://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Lymphocytic-Leukaemia/eUpdate-Treatment-Recommendations.

2. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study

3. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

4. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

5. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia